Investor day prep at Merck includes a new strategy to pick up the pace on M&A — report
Merck’s recent deals to buy up two bolt-on biotechs — Tilos and Peloton — weren’t an aberration. Instead, both acquisitions mark a new strategy to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
